Skip to main content
Funded Studies

Anne Urfer-Buchwalder, PhD

Founder and President at Selonterra, Inc.

Location: San Mateo, CA United States

Dr. Anne Urfer-Buchwalder is a pioneer in mammalian gene expression and genetics with more than 25 years of experience in biotechnology start-ups, pharmaceutical companies and premier academic institutions. She holds a PhD from the University of Strasbourg (France) and is the founder and president of Selonterra, Inc., a San Francisco Bay Area-based biotechnology company focused on the discovery of novel therapies for complex neurodegenerative disorders with strong genetic links, notably Parkinson’s and Alzheimer’s diseases. Selonterra’s unique innovation is that genetic variants linked to neurodegeneration act at the DNA level by dysregulating the expression of nearby genes. Prior to Selonterra, she was among the first employees of Transgene SA (France), was a scientist at Sandoz (Novartis), at the Biocenter of the University of Basel, at the Beckman Research Center of the City of Hope and later joined Spectra-Biomedical Inc.

Associated Grants

  • (SUPPLEMENT) Innovative Therapies for Parkinson’s Disease Through a Novel, Unexploited Gene Expression Mechanism Rooted in Human Genetics Enabling a Precision-medicine Approach


  • Exploiting a Novel Mechanism for Gene Regulation to Develop Innovative, Targeted Therapies for Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.